Obinutuzumab/chlorambucil in the first-line treatment of older CLL patients

Obinutuzumab/chlorambucil is superior to rituximab/chlorambucil in the first-line treatment of older patients with chronic lymphocytic leukaemia (CLL) suffering from comorbidities. Obinutuzumab/chlorambucil combination led to a prolongation in progression-free survival which was the study primary endpoint. Secondary efficacy endpoints of higher response rate and minimal residual disease negativity rate were also achieved. Prolonged overall survival was seen when compared obinutuzumab/chlorambucil vs. chlorambucil alone. The final results of the phase III CLL11 trial were presented during a Plenary Session at the 55th American Society of Hematology (ASH) Annual Meeting (7-10 December 2013, New Orleans, USA). Read more here.